Intravaginal Artesunate for the Treatment of HPV+ High Grade Cervical Intraepithelial Neoplasia (CIN2/3)
Status:
Completed
Trial end date:
2018-11-06
Target enrollment:
Participant gender:
Summary
This phase I research protocol is designed to assess immunogenicity and clinical endpoints in
patients with human papillomavirus (HPV) 16 cervical intraepithelial neoplasia (CIN)2/3. The
protocol tests the use of artesunate in suppository formulation applied intravaginally in
patients with cervical dysplasia (CIN2/3).
The primary endpoint is to determine and evaluate the safety, tolerability, and feasibility
of intravaginal administration of artesunate in health women with CIN2/3.
Phase:
Phase 1
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins